Status:
UNKNOWN
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Anlotinib
Anti-PD-1 Antibody
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to...
Eligibility Criteria
Inclusion
- locally advanced or metastatic pancreatic cancer (PC),
- histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma,
- failed to second-line chemotherapy for PC,
- 18-75 years of age,
- an Eastern Cooperative Oncology Group performance status score of 0 to 1,
- adequate organ functions
Exclusion
- had received PD 1 /CTLA 4 antibody treatment
- had received anti-VEGFR inhibitors or antibodies
Key Trial Info
Start Date :
May 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 29 2024
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04803851
Start Date
May 12 2021
End Date
June 29 2024
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100032